SG Americas Securities LLC Invests $680,000 in C4 Therapeutics, Inc. (NASDAQ:CCCC)

SG Americas Securities LLC bought a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 425,096 shares of the company's stock, valued at approximately $680,000. SG Americas Securities LLC owned about 0.60% of C4 Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Rhumbline Advisers lifted its stake in shares of C4 Therapeutics by 4.6% in the 4th quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock worth $360,000 after acquiring an additional 4,366 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in C4 Therapeutics during the 4th quarter worth approximately $83,000. Charles Schwab Investment Management Inc. raised its stake in shares of C4 Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 486,366 shares of the company's stock worth $1,751,000 after buying an additional 3,437 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of C4 Therapeutics by 16.5% in the 4th quarter. M&T Bank Corp now owns 132,715 shares of the company's stock valued at $478,000 after buying an additional 18,808 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in shares of C4 Therapeutics by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 30,150 shares of the company's stock valued at $109,000 after buying an additional 3,024 shares during the period. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Stock Up 6.1%

CCCC stock traded up $0.09 on Tuesday, reaching $1.56. 941,694 shares of the company's stock were exchanged, compared to its average volume of 1,337,439. The stock has a fifty day moving average of $1.47 and a 200-day moving average of $2.46. The firm has a market cap of $110.77 million, a PE ratio of -1.06 and a beta of 2.93. C4 Therapeutics, Inc. has a twelve month low of $1.09 and a twelve month high of $7.66.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.11. The business had revenue of $7.20 million for the quarter, compared to the consensus estimate of $3.54 million. C4 Therapeutics had a negative return on equity of 45.86% and a negative net margin of 259.60%. On average, equities research analysts predict that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.